JP Morgan Chase’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-47
| Closed | – | – | 7212 |
|
|
2022
Q2 | $0 | Sell |
47
-341
| -88% | -$1.33K | ﹤0.01% | 7266 |
|
|
2022
Q1 | $1K | Sell |
388
-1,163
| -75% | -$5.07K | ﹤0.01% | 6532 |
|
|
2021
Q4 | $7K | Buy |
1,551
+1,504
| +3,200% | +$6.27K | ﹤0.01% | 6391 |
|
|
2021
Q3 | $0 | Sell |
47
-71,542
| -100% | -$284K | ﹤0.01% | 7103 |
|
|
2021
Q2 | $306K | Sell |
71,589
-12,043
| -14% | -$51.6K | ﹤0.01% | 5006 |
|
|
2021
Q1 | $355K | Buy |
83,632
+17,610
| +27% | +$97K | ﹤0.01% | 4873 |
|
|
2020
Q4 | $256K | Sell |
66,022
-6,997
| -10% | -$29.9K | ﹤0.01% | 4715 |
|
|
2020
Q3 | $290K | Sell |
73,019
-7,062
| -9% | -$29.3K | ﹤0.01% | 4212 |
|
|
2020
Q2 | $341K | Sell |
80,081
-12,830
| -14% | -$78.1K | ﹤0.01% | 4024 |
|
|
2020
Q1 | $390K | Sell |
92,911
-17,329
| -16% | -$109K | ﹤0.01% | 3947 |
|
|
2019
Q4 | $434K | Sell |
110,240
-9,850
| -8% | -$58.2K | ﹤0.01% | 4308 |
|
|
2019
Q3 | $1.06M | Buy |
120,090
+5,451
| +5% | +$51.5K | ﹤0.01% | 3805 |
|
|
2019
Q2 | $1.03M | Sell |
114,639
-7,992
| -7% | -$60.2K | ﹤0.01% | 3851 |
|
|
2019
Q1 | $789K | Sell |
122,631
-8,046
| -6% | -$52.4K | ﹤0.01% | 3947 |
|
|
2018
Q4 | $1.23M | Sell |
130,677
-7,740
| -6% | -$116K | ﹤0.01% | 3613 |
|
|
2018
Q3 | $2.79M | Buy |
138,417
+8,388
| +6% | +$219K | ﹤0.01% | 3220 |
|
|
2018
Q2 | $3.79M | Sell |
130,029
-7,115
| -5% | -$220K | ﹤0.01% | 2904 |
|
|
2018
Q1 | $4.08M | Buy |
137,144
+133,372
| +3,536% | +$4.3M | ﹤0.01% | 2750 |
|
|
2017
Q4 | $121K | Buy |
+3,772
| New | +$123K | ﹤0.01% | 4591 |
|
|
2017
Q1 | – | Sell |
-840
| Closed | -$15K | – | 5467 |
|
|
2016
Q4 | $15K | Buy |
+840
| New | +$16.1K | ﹤0.01% | 4749 |
|
JP Morgan Chase's LJPC Position: Q3 2022 in Review
JP Morgan Chase sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 47 shares.
JP Morgan Chase first reported a position in LJPC in Q4 2016 and held it in 20 quarters. The position peaked at $4.08M in Q1 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- JP Morgan Chase reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- JP Morgan Chase sold 47 La Jolla Pharmaceutical Company shares in Q3 2022.
- JP Morgan Chase first reported a position in La Jolla Pharmaceutical Company in Q4 2016 and held it in 20 quarters.
- JP Morgan Chase's La Jolla Pharmaceutical Company position peaked at $4.08M in Q1 2018.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.